Form 4: PTC Therapeutics Exec Sells Shares Post-Option Exercise
Insider Transaction Report
PTC Therapeutics' Executive VP and CLO, Mark Elliott Boulding, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 plan.
Summary
- Mark Elliott Boulding, Executive VP and Chief Legal Officer of PTC Therapeutics, Inc. (PTCT), engaged in transactions involving the company's common stock on November 17, 2025.
- Boulding exercised stock options to acquire 2,812 shares of common stock at an exercise price of $25.69 per share.
- Following the option exercise, Boulding sold a total of 2,812 shares of common stock in multiple transactions.
- The sales occurred at weighted average prices of $75.64 for 1,843 shares, $76.53 for 777 shares, and $77.18 for 192 shares.
- These transactions were executed pursuant to a Rule 10b5-1 plan adopted by Boulding on December 5, 2024.
- After these transactions, Boulding's direct beneficial ownership of common stock decreased from 106,713 shares to 103,901 shares.
- His direct beneficial ownership of stock options (right to buy) decreased from 28,126 (2,812 exercised + 25,314 remaining) to 25,314.
Sentiment
Score: 5
Explanation: The filing reports a routine insider transaction involving the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 plan. This type of transaction is generally neutral in sentiment, reflecting executive compensation and personal financial planning rather than a direct signal about company performance or future prospects.
Positives
- The executive exercised options at $25.69 and sold shares at significantly higher prices ranging from $75.64 to $77.18, indicating a substantial profit on the exercised shares.
- The transactions were conducted under a pre-arranged Rule 10b5-1 plan, which suggests planned, not opportunistic, selling, and provides an affirmative defense against insider trading allegations.
Negatives
- An executive officer sold a significant number of shares, which could be interpreted by some investors as a lack of confidence, although it was part of a pre-arranged plan.
Risks
- NA
Future Outlook
NA
Industry Context
This Form 4 filing details an executive's personal stock transactions, which is a routine disclosure for publicly traded companies. It does not provide broader industry context or trends, focusing solely on individual insider trading activity.
Stakeholder Impact
- Shareholders: May observe a slight decrease in executive ownership, though the transaction is pre-planned and common for executive compensation, thus unlikely to signal a change in company fundamentals.
- Employees: No direct impact.
- Customers/Suppliers/Creditors: No direct impact.
Key Dates
| Date | Description |
|---|---|
| 2024-02-15 | Grant date of the stock option. |
| 2024-12-05 | Date Rule 10b5-1 plan was adopted by the Reporting Person. |
| 2025-02-15 | First vesting date for 25% of the shares underlying the option. |
| 2025-05-15 | Start of successive three-month vesting periods for 6.25% of original shares underlying the option. |
| 2025-11-17 | Date of stock option exercise and subsequent common stock sales. |
| 2025-11-19 | Signature date of the filing. |
| 2034-02-14 | Expiration date of the stock option. |
Keywords
insider trading, stock options, executive compensation, PTCT, PTC Therapeutics, Form 4, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.